These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 8525189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portolés J, Gomez-Martino JR.
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [Abstract] [Full Text] [Related]

  • 3. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 4. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
    Sułowicz W, Drozdz M, Hanicki Z, Kraśniak A, Kuźniewski M.
    Przegl Lek; 1992 Jun; 49(1-2):50-3. PubMed ID: 1455007
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Is it necessary to supplement with folic acid patients in chronic dialysis treated with erythropoietin?].
    Duclos J, Sieberth HG, Mann H.
    Rev Med Chil; 1993 Jan; 121(1):30-5. PubMed ID: 8235161
    [Abstract] [Full Text] [Related]

  • 7. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
    Gentil MA, Pérez-Valdivia MA, González-Roncero FM, López-Mendoza M, Cabello V, Bernal G, Suñer M, Pereira P.
    Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 13. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.
    Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
    [Abstract] [Full Text] [Related]

  • 14. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
    García Martín F, Carrascosa Vallejo T, Martín Escobar E, Val Begueria J, Martín Hernández R, de Arriba G, Teno C, Salvatierra J.
    Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
    [Abstract] [Full Text] [Related]

  • 16. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.
    Bunke M, Bartlett DK, Brier ME, Golper TA.
    Adv Perit Dial; 1993 May; 9():331-5. PubMed ID: 8105957
    [Abstract] [Full Text] [Related]

  • 17. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
    Stefanovic V, Mitić-Zlatkovic M, Radivojevic J, Vlahovic P.
    Ren Fail; 2005 May; 27(3):283-8. PubMed ID: 15957544
    [Abstract] [Full Text] [Related]

  • 18. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 May; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 19. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E, Ofsthun N, Lazarus JM.
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [Abstract] [Full Text] [Related]

  • 20. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
    Zehnder C, Blumberg A.
    Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.